GlaxoSmithKline PLC’s proposal to market the first mouth spray nicotine replacement therapy available in the US has been delayed by the Food and Drug Administration questions about the OTC product’s Drug Facts label.
A GSK representative on 8 January told HBW Insight that the firm plans to make changes the FDA requested in...








